Physician profile
Nancy Rubin
NPI 1003980947
$757.22
in general payments reported to CMS, 2019-2025
17 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.92 · 2021: $133 · 2022: $127 · 2023: $192 · 2024: $42.22 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341 · Education: $95.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.84 |
| Education | $95.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $188.70 | 2023-2025 | Opdivo, Eliquis |
| Gilead Sciences, INC. | $107.87 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $56.02 | 2021-2023 | Enhertu |
| Novocure INC. | $47.57 | 2023-2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Tesaro, INC. | $44.27 | 2019 | |
| Lilly USA, LLC | $42.14 | 2019-2021 | |
| Pfizer INC. | $39.08 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $31.87 | 2025 | Clonoseq |
| Incyte Corporation | $27.05 | 2022 | |
| Cti Biopharma Corp. | $26.78 | 2023 | Vonjo |
| Abbvie INC. | $25.37 | 2021 | |
| G1 Therapeutics, INC. | $23.53 | 2022 | |
| Emd Serono, INC. | $22.41 | 2022 | |
| Sobi, INC | $21.29 | 2022 | |
| Glaxosmithkline, LLC. | $19.86 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $19.37 | 2021 | |
| Genentech USA, INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.